San Diego, CA — September 15, 2025 — Leads & Copy — Abzena has expanded its AbZelectPRO™ cell line development (CLD) platform with the launch of two next-generation Glutamine Synthetase (“GS”) knockout CHO-K1 expression systems, including a double knockout ADCC+ platform for afucosylated proteins.
The new GS knockout cell lines will enhance speed, scalability, and flexibility for biopharma customers. The new GS knockout platforms, named AbZelectPRO™-KO and AbZelectPRO™-KO+, are available as a standalone CLD offering or as a fully integrated GMP program, with transparent pricing to IND with no royalty fees.
According to Campbell Bunce, CSO of Abzena, the addition of these new GS knockout cell lines to the AbZelectPRO™ CLD platform sets a new standard of excellence. Frank Pieper, CEO of ProteoNic, said that ProteoNic’s technology boosts productivity in CHOSOURCE™ and other cell lines and strengthens the value of this offering for biopharma customers.
Bryan Kipp, SVP Technology & Licensing, Revvity, said that Abzena’s new expanded cell line development platform, inclusive of Revvity’s CHOSOURCETM cell lines, directly targets ongoing major challenges for customers, enhancing productivity and flexibility.
Revvity’s CHOSOURCE™ Glutamine Synthetase (GS) knockout cell line is an industry standard, cGMP-manufactured CHO-K1-derived suspension cell line. It has been referenced in over 90 IND filings and is currently featured in four approved drugs on the market.
Campbell Bunce, CSO of Abzena.
Frank Pieper, CEO of ProteoNic.
Bryan Kipp, SVP Technology & Licensing, Revvity.
Source: Abzena
